What type of study is this?

This is a Cohort Study study (also classified as: Human Clinical Trial).

December 8, 2025Blood

Real-world experience with first-line regimens in transplant-ineligible patients with multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study reports high response rates and low early mortality in transplant-ineligible multiple myeloma patients using DRd and RVd.

Overall response rates with DRd and RVd reached approximately 95%, indicating the effectiveness of these regimens.
The observational study assessed treatment responses in 1,085 transplant-ineligible patients with multiple myeloma over several years.
Significantly lower early mortality rates were observed with DRd, highlighting its potential advantage as a primary treatment option.
These findings emphasize the importance of evaluating progression-free survival as DRd's long-term efficacy data becomes available.

Gul et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study reports high response rates and low early mortality in transplant-ineligible multiple myeloma patients using DRd and RVd.

Overall response rates with DRd and RVd reached approximately 95%, indicating the effectiveness of these regimens.
The observational study assessed treatment responses in 1,085 transplant-ineligible patients with multiple myeloma over several years.
Significantly lower early mortality rates were observed with DRd, highlighting its potential advantage as a primary treatment option.
These findings emphasize the importance of evaluating progression-free survival as DRd's long-term efficacy data becomes available.

Gul et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark